HLA-B27 Positivity Did Not Influence CLL, SLL Outcomes
Further studies needed to look at relevance outside of the transplant-eligible population.
Leukemia
Use of MRD Status Following Obinutuzumab/Ibrutinib to Guide Subsequent Therapy Selection in CLL
This trial employed chemotherapy-free induction therapy followed by assessment of MRD status to triage patients for subsequent therapy with or without chemotherapy.
After Long-Term Ibrutinib Therapy for CLL, BTK Mutations May Signal Progression
Some patients with BTK mutations could benefit from treatment changes at earlier stages.
Predicting Bleeding Risk in Acute Myeloid Leukemia With Thrombocytopenia With Platelet Function Tests
Platelet aggregation and platelet activation were both independently associated with bleeding risk.
Identifying Risk Factors for Second Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia
Rates of leukemia-free and overall survival were 20% and 30%, respectively, at 2 years and 12% and 14%, respectively, at 5 years.
Study Found Gilteritinib Superior to Salvage Chemotherapy in FLT3-Mutated Refractory AML
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
Efficacy of Bosutinib in Chronic Myeloid Leukemia Resistant to Prior Treatment
A substantial proportion of patients who received bosutinib achieved major cytogenetic response and molecular response within 1 year.
Induction Chemotherapy Intensity May Not Influence Survival in Acute Myeloid Leukemia
Intensity of induction chemotherapy was associated with measurable residual disease negativity but not overall survival.
Long-Term Outcomes of Ibrutinib in Chronic Lymphocytic Leukemia
Patients receiving ibrutinib had an overall response rate of 8% and median progression-free survival of 44.1 months.
Treatment-Free Remission After Nilotinib May Be Durable in Chronic Myeloid Leukemia
Among 126 patients who entered treatment-free remission, 58 remained in remission at 192 weeks.
